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ABSTRACT We studied the effects of natural ceramide and a series of ceramide analogs with different acyl chain lengths
on the activity of rat brain protein kinase C (PKC) and on the structure of bovine liver phosphatidylcholine (BLPC)/
dipalmitoylphosphatidylcholine (DPPC)/dipalmitoylphosphatidylserine (DPPS) (3:1:1 molar ratio) bilayers using 2H-NMR and
specific enzymatic assays in the absence or presence of 7.5 mol % diolein (DO). Only a slight activation of PKC was observed
upon addition of the short-chain ceramide analogs (C2-, C6-, or C8-ceramide); natural ceramide or C16-ceramide had no
effect. In the presence of 7.5 mol % DO, natural ceramide and C16-ceramide analog slightly attenuated DO-enhanced PKC
activity. 2H-NMR results demonstrated that natural ceramide and C16-ceramide induced lateral phase separation of gel-like
and liquid crystalline domains in the bilayers; however, this type of membrane perturbation has no direct effect on PKC
activity. The addition of both short-chain ceramide analogs and DO had a synergistic effect in activating PKC, with maximum
activity observed with 20 mol % C6-ceramide and 15 mol % DO. Further increases in C6-ceramide and/or DO concentrations
led to decreased PKC activity. A detailed 2H-NMR investigation of the combined effects of C6-ceramide and DO on lipid
bilayer structure showed a synergistic effect of these two reagents to increase membrane tendency to adopt nonbilayer
structures, resulting in the actual presence of such structures in samples exceeding 20 mol % ceramide and 15 mol % DO.
Thus, the increased tendency to form nonbilayer lipid phases correlates with increased PKC activity, whereas the actual
presence of such phases reduced the activity of the enzyme. Moreover, the results show that short-chain ceramide analogs,
widely used to study cellular effects of ceramide, have biological effects that are not exhibited by natural ceramide.
INTRODUCTION
PKC is a serine/threonine kinase family involved in many
cellular responses, such as cell proliferation (Bishop and
Bell, 1988; Nishizuka, 1992; Murray et al., 1993), cell
differentiation (William et al., 1990; Aihara et al., 1991;
Nishizuka, 1992; Murray et al., 1993), and apoptosis (Mc-
Conkey et al., 1989; Grant et al., 1992; Lucas and Sa´nchez-
Margalet, 1995; Lavin et al., 1996). Through phosphoryla-
tion of other signaling protein intermediates, PKC is
involved in a variety of intracellular signal transduction
pathways, including the release of the active form of NF-B
(Buchner, 1995), and the activation of Raf-1 (Kolch et al.,
1993; Carroll and May, 1994; Zou et al., 1996). To date, at
least 12 PKC isozymes have been discovered (Dekker and
Parker, 1994). Differences in tissue distribution, intracellu-
lar localization, and cofactor requirements among PKC
isozymes suggest the possibility that these isozymes may
play distinct roles in various cellular responses and in the
complex cellular signaling network (Hug and Sarre, 1993).
The activity of the conventional PKCs can be modulated
by lipophilic molecules, such as fatty acids (Lester, 1990;
Hardy et al., 1994; Goldberg and Zidovetzki, 1997, 1998),
cholesterol (Bolen and Sando, 1992), sphingosine (Hannun
et al., 1986; Khan et al., 1991), and lysophosphatidic acid
(Sando and Chertihin, 1996). A number of studies corre-
lated the perturbation of membrane structure induced by
these molecules with their effect on PKC activity (Epand
and Lester, 1990; Bolen and Sando, 1992; Sando et al.,
1992; Zidovetzki and Lester, 1992; Senisterra and Epand,
1993; Stubbs and Slater, 1996; Zidovetzki, 1997). The
mechanism of action of the best-studied PKC cofactor,
DAG, includes DAG-induced changes in the lipid mem-
brane structure such as increased tendency to form nonbi-
layer lipid phases (Epand and Bottega, 1988; Goldberg et
al., 1994), changes in the phospholipid headgroup confor-
mation (Goldberg et al., 1995), and the presence of DAG-
poor and DAG-rich lipid domains (Dibble et al., 1996;
Hinderliter et al., 1997).
Another intracellular second messenger, ceramide, is the
product of the hydrolysis of sphingomyelin by sphingomy-
elinase, initiated by extracellular stimuli including tumor
necrosis factor- (Kim et al., 1991; Kolesnick and Golde,
1994), and interleukin-1 (Mathias et al., 1993). Ceramide is
implicated in cell proliferation (Olivera et al., 1992; Sasaki
et al., 1995; Auge et al., 1996), cell differentiation (Riboni
et al., 1995), and apoptosis (for a review, see Obeid and
Hannun, 1995). In addition to activating its intracellular
target, ceramide-activated protein kinase (Kolesnick and
Hemer, 1990; Mathias et al., 1991; Yao et al., 1995), cer-
amide also modulates the activity of other enzymes in-
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volved in signal transduction, such as phosphatase (Wolff et
al., 1994), phospholipase A2 (Huang et al., 1996, 1998), and
phospholipase D (Venable et al., 1996; Abousalham et al.,
1997). Ceramide is also involved in transducing signals
toward the cell nucleus via NF-B activation (Schu¨tze et al.,
1994), c-myc downregulation (Kim et al., 1991), and c-jun/
AP-1 activation (Sawai et al., 1995). Ceramide has a struc-
ture similar to DAG and induces perturbation of the mem-
brane structure similarly to long-chain DAGs (Huang et al.,
1996, 1998; Veiga et al., 1999).
There are few studies and no consensus on the effect of
ceramide on PKC. Lozano et al. (1994) reported that PKC
is activated by natural ceramide in vitro and by treatment
with sphingomyelinase in National Institutes of Health-3T3
fibroblasts with subsequent activation of NF-B. In con-
trast, PKC is inactivated by synthetic cell-permeable C2-
and C6-ceramides in Molt-4 cells; in in vitro systems, C6-
ceramide did not affect PKC activity (Lee et al., 1996).
The translocation of PKC, but not of PKC, is blocked by
treatment with sphingomyelinase or C2-ceramide in mouse
epidermal (HEL-37) and human skin fibroblast (SF 3155)
cells (Jones and Murray, 1995). Sawai et al. (1997) sug-
gested that C2-ceramide induces cytosolic translocation of
PKC and , which leads to apoptosis in human leukemia
cell lines. Furthermore, Chmura et al. (1996) have suggested
antagonistic roles of PKC and ceramide in apoptosis in
murine B-cell lymphoma, WEHI-231.
In the present paper we examined the effect of natural
ceramide, and its long-chain and short-chain cell-permeable
analogs, on the membrane structure and the activity of rat
brain PKC in the absence or presence of the PKC cofactor
DO. We have found that short-chain ceramide analogs have
qualitatively different effects from natural ceramide and
C16-ceramide on both PKC activity and lipid bilayer struc-
ture. The effects of the ceramides on PKC activity are
dependent on chain length and can be correlated with cer-
amide-induced perturbations in the lipid bilayer structure.
MATERIALS AND METHODS
Materials
Synthetic C2-ceramide, C6-ceramide, C8-ceramide, and C16-ceramide were
from Biomol (Plymouth Meeting, PA). BLPC, DPPC, DPPS, DPPC-d62,
and DO were purchased from Avanti Polar Lipids (Alabaster, AL). PKC
extracted from rat brain was purchased from Calbiochem (La Jolla, CA).
Histone 1 (Sigma type III-S), adenosine triphosphate, sphingomyelin ex-
tracted from bovine brain, and morpholinopropanesulfonic acid (MOPS)
were obtained from Sigma Co. (St. Louis, MO).
Preparation of multilamellar vesicles for
PKC assay
The multilamellar vesicles had a composition of 3:1:1 (molar ratios)
BLPC/DPPC/DPPS with DO and/or ceramides added as mol % to the
phospholipids. The vesicles were prepared by mixing all lipids in chloro-
form. The chloroform was then evaporated under a stream of dry nitrogen
and the samples were placed under a vacuum (1 mtorr) overnight. Each
sample was fully hydrated with 75 L 20 mM MOPS (pH 7.4), 5 mM
MgCl2, 40 M Ca
2. The hydrated lipids were temperature-equilibrated at
30°C in a water bath.
Preparation of multilamellar vesicles for
NMR spectroscopy
The compositions of lipids used in NMR measurements were identical to
the PKC samples, except for the substitution of DPPC-d62 for DPPC. After
mixing the lipids in chloroform, the solvent was evaporated with a stream
of dry nitrogen. Lipids were then dissolved in benzene/methanol (20:1,
volume ratio), quickly frozen with liquid nitrogen, and lyophilized under a
vacuum (1 mtorr) for at least 8 h. Samples were then fully hydrated with
50 L 40 mM MOPS (pH 7.4), 65 mM MgCl2 buffer prepared in
2H-
depleted H2O (1:2 w/w lipid/buffer). In order to achieve equivalent satu-
ration of Mg2 binding to PS for NMR samples and PKC samples, NMR
samples were prepared with 65 mM Mg2 according to the Mg2-PS
binding constant of 1.6  103 M and stoichiometry of 2:1 (PS/Mg2)
(Portis et al., 1979). A uniform lipid suspension was obtained by five
freeze-thaw cycles (Westman et al., 1982; Mayer et al., 1985). In some
samples 1-palmitoyl, 2-oleoylPC (POPC), perdeuterated at the palmitic
chain, was added substituting for 33% of BLPC content. The 2H-NMR
results obtained with these samples were identical to those obtained with
corresponding DPPC-d62-containing samples, allowing for the obvious
difference between the 2H-NMR spectra of POPC, deuterated at only one
acyl chain, and DPPC-d62, deuterated at both.
Protein kinase C assay
PKC activity was measured by phosphorylation of the exogenous substrate
histone 1 according to Sando and Chertihin (1996), with modifications.
Briefly, samples were temperature-equilibrated with substrate and ATP
with 0.6 Ci [-32P]ATP/sample (Dupont-NEN, Boston, MA) before
performing the assay, which was initiated by adding PKC. The reaction
was allowed to proceed for 5 min at 30°C, and was stopped by blotting 60
L of the sample onto Whatman P-81 (Whatman, Fairfield, NJ) cation
exchange filter paper. In order to remove unreacted ATP, the filters were
washed with 500 mL 50 mM NaCl four times. The reaction kinetics were
linear under all conditions of the assay. The amount of 32P transferred to
histone was determined by liquid scintillation counting. A sample contain-
ing the BLPPC/DPPC/DPPS mixtures and 15 mol % DO was included in
every assay as an internal standard, and the results are expressed relative to
the activity obtained with this sample, taken as 100% activity.
NMR measurements
2H-NMR spectra were acquired at 11.74 T (corresponding to 76.77 MHz
2H frequency) on a General Electric GN500 spectrometer. 2H-NMR spec-
tra were acquired with a high-power probe using the standard quadrupole
echo sequence (Davis et al., 1976). The spectral width was 500 kHz and the
refocusing time was 60 s, with a 90° pulse of 3.5 s and a recycle time
of 200 ms.
Phase composition analyses
Spectra exhibiting the coexistence of liquid-crystalline bilayer and nonbi-
layer phases were analyzed by spectral subtraction similar to the method of
Morrow and Davis (1988) as previously described (Goldberg and
Zidovetzki, 1998). All spectra were scaled to contain the same spectral
area, and then pure-phase spectra were digitally subtracted from a multiple-
phase spectrum. The amount of subtraction necessary to remove the com-
ponent from the multiple-phase spectrum indicated the fraction of lipid
occupying that phase. No simulated spectra were used. Pure nonbilayer
phase spectra were obtained from samples exhibiting L/nonbilayer phase
components, and digitally subtracting out the unwanted phase. In order to
compensate for differences in the width of isotropic peaks and changes in
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quadrupole splittings of L phase between samples, pure spectra could be
modulated by a width constant (keeping total spectral area fixed) to best
match the spectrum being analyzed.
RESULTS
The effects of natural and the synthetic ceramides on PKC
activity in the absence or presence of DO are shown in Fig.
1. The activity was normalized relative to the activity ex-
hibited with the samples containing 15 mol % DO included
in each assay as internal standards. In the absence of DO,
the control BLPC/DPPC/DPPS samples supported only 9%
of the PKC activity observed in these DO-containing sam-
ples. Addition of natural ceramide resulted in a concentra-
tion-dependent decrease of the activity down to 3% in the
presence of 25 mol % natural ceramide (Fig. 1 A). In the
presence of 7.5 mol % DO, the addition of natural ceramide
resulted in a decrease of PKC activity from 35% to 16%
(Fig. 1 A). In the case of C16-ceramide the observed ten-
dency for decrease in PKC activity was not significant in the
absence of DO; a small but significant reduction in DO-
enhanced activity was observed at the highest tested C16-
ceramide concentration of 25 mol % (data not shown).
A different picture was observed in the cases of the
short-chain ceramide analogs (Fig. 1, B and C). In the
absence of DO, C2-ceramide did not affect PKC activity up
to 25 mol % (Fig. 1 B), whereas at 25 mol % C6-ceramide
increased PKC activity from 9% to 52% (Fig. 1 C), and
C8-ceramide to 40% (data not shown). A dramatic effect of
the short-chain ceramides was observed in the presence of
7.5 mol % DO. Each ceramide induced concentration-de-
pendent increases of PKC activity from 30% activation in
the absence of the ceramides to 68%, or 123% in the
presence of 25 mol % C2- or C6-ceramide, respectively (Fig.
1, B and C) and to 144% in the presence of C8-ceramide
(data not shown). The effects were already significant at 5
mol % ceramide.
The effects of the acyl chain length of the synthetic
ceramide analogs (at 15 mol %) are summarized in Fig. 2.
In the presence of 7.5 mol % DO, short-chain (C2-, C6-, C8-)
ceramides synergistically increased DO-induced PKC acti-
vation. The effect was most pronounced in the cases of C6-
or C8-ceramide, which increased DO-enhanced PKC activ-
ity by more than threefold. Similarly to natural ceramide,
C16-ceramide did not affect PKC activity.
We further investigated the synergistic effect of DO and
C6-ceramide on PKC activity by varying concentrations of
both DO and C6-ceramide (Fig. 3). C6-ceramide alone
showed only a minor activation of PKC, which agrees with
the results shown in Fig. 1. As expected, DO alone activated
PKC in a concentration-dependent manner reaching a max-
imum at 20 mol %. At lower DO concentrations (5–15 mol
%), C6-ceramide synergistically enhanced the effects of DO
in a concentration-dependent manner, reaching the maxi-
mum observed activation at 15 mol % DO/20 mol % C6-
ceramide. Further increase in DO and/or C6-ceramide con-
centration led to a decrease in PKC activity (Fig. 3).
The relationship between PKC activity and membrane
physical properties was studied by 2H-NMR using DPPC-
FIGURE 1 Dependence of PKC activity on the concentration of cer-
amides in the absence () or presence (‚) of 7.5 mol % DO in BLPC/
DPPC/DPPS bilayers. 100% PKC activity was defined as the activity in the
BLPC/DPPC/DPPS samples with the addition of 15 mol % DO, included
in every assay as an internal standard. The samples were run in triplicates
at 30°C. The error bars correspond to SEM. (A) natural ceramide; (B)
C2-ceramide; (C) C6-ceramide.
FIGURE 2 Dependence of PKC activity on synthetic ceramide side-
chain length at 15 mol % ceramide in the presence of 7.5 mol % DO in
PC/PS bilayers. The leftmost point corresponds to the normalized activity
of PKC without ceramides. The rightmost point corresponds to the natural
ceramide.
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d62 incorporated into PC/PS bilayers. The
2H-NMR spectra
of DPPC-d62 in PC/PS bilayers in the absence or presence of
C6-ceramide and/or DO are shown in Fig. 4. An
2H-NMR
spectrum of DPPC-d62 is the superposition of axially aver-
aged powder patterns that correspond to the deuterons at
different positions along the DPPC-d62 acyl chains (Davis,
1979). The control spectrum of BLPC/DPPC-d62/DPPS (3:
1:1 molar ratio) multilamellar vesicles at 30°C shows a
typical liquid crystalline bilayer profile (Fig. 4 A). At 60°C,
the lipids remained in the liquid crystalline phase (Fig. 4 B).
The presence of 15 mol % DO or 20 mol % C6-ceramide,
the concentrations that correspond to the maximum PKC
activation (see Fig. 3), did not induce nonbilayer lipid
phases at temperatures up to 60°C (Fig. 4, C–F). However,
the addition of both 15 mol % DO and C6-ceramide resulted
in the induction of 21% of the isotropic lipid phase at 60°C
(Fig. 4 H). This indicates that the corresponding bilayers
have an increased propensity to form such a phase already
at 30°C. A different picture was obtained upon increasing
both DO and C6-ceramide concentrations to 25 mol %,
corresponding to the decreased PKC activity (cf. Fig. 3).
Addition of 25 mol % DO to the PC/PS bilayers resulted in
the formation of nonbilayer phases, comprising 12% of the
2H-NMR intensity at 30°C (Fig. 5 A), whereas no nonbi-
layer phases were induced by 25 mol % C6-ceramide (Fig.
5 B). In the presence of both 25 mol % C6-ceramide and 25
mol % DO at 30°C, the proportion of the lipids in nonbi-
layer phases increased to 42% (Fig. 5 C), demonstrating the
synergistic effect of these two reagents in inducing nonbi-
layer lipid phases. In all cases, identical results were ob-
tained using DPPS-d62 as an
2H-NMR label, indicating that
DO and ceramides do not preferentially affect PC or PS
lipid components (data not shown). In contrast to the effect
of C6-ceramide, natural ceramide and DO did not induce
nonbilayer phases at either 30 or 60°C (Fig. 6). The broad
component observed at 30°C in the spectrum containing
natural ceramide without (not shown) or with DO (Fig. 6 A)
corresponds to the bilayers in the gel phase, superimposed
with the narrower spectrum of the lipids in the liquid crys-
talline (L) phase. Such a superposition is indicative of
coexistence of the laterally separated lipid domains with
different fluidities, and was described by us previously as an
effect of long-chain and natural ceramides on BLPC and
DPPC bilayers (Huang et al., 1996, 1998).
DISCUSSION
The purpose of the present work was to investigate the
effect of ceramide analogs on modulating PKC activity and
to examine the relationship between this effect and the
membrane perturbations induced by these ceramides. Ac-
cording to the model of the activation of Ca2-dependent
PKC proposed in many studies (Hannun and Bell, 1986;
Stabel and Parker, 1991; Bell and Burns, 1991; Zidovetzki
and Lester, 1992), the release of a micromolar level of Ca2
triggers the binding of an inactive form of PKC to mem-
brane bilayer, and the subsequent binding to PS and DAG
facilitates PKC to undergo a conformational change and
form an active form of the enzyme. Based on this model,
extensive studies have suggested that local alterations of the
physical properties of the membrane bilayers play a vital
role in modulating the activity of PKC (Epand and Lester,
1990; Bolen and Sando, 1992; Zidovetzki and Lester, 1992;
Senisterra and Epand, 1993; Slater et al., 1994). It has been
reported that several lipophilic molecules, such as chloro-
form (Lester and Baumann, 1991), phosphatidylethanol-
amine (PE) (Epand and Bottega, 1988), unsaturated phos-
pholipid (Bolen and Sando, 1992), cholesterol (Bolen and
Sando, 1992), lysophosphatidic acid (Sando and Chertihin,
1996), and unesterified fatty acids (Goldberg and
Zidovetzki, 1997; 1998) modulate the enzyme’s activity.
Furthermore, DAG-induced membrane perturbations play
an important role in the mechanism of PKC activation
(Epand, 1985; Das and Rand, 1986; Goldberg et al., 1994;
see Zidovetzki, 1997, for a review). Among different types
of membrane perturbations induced by DAGs, the promo-
tion of nonbilayer lipid phases has been long proposed to be
associated with the activation of PKC. For example, low-
ering the liquid-crystalline bilayer phase (L)-to-hexagonal
phase (HII) transition temperature (TH) by the addition of
certain lipid molecules, such as DO (Epand et al., 1988) or
1-oleoyl, 2-docosahexaenoylPE, into the lipid system leads
to an increase in PKC activity (Giorgione et al., 1995). Our
previous studies also observed a correlation between PKC
activation and the increased tendency to form nonbilayer
lipid phases (Goldberg et al., 1994; Goldberg and
Zidovetzki, 1998). Epand et al. (1988) have suggested that
uncharged zwitterionic hexagonal phase promoters are gen-
erally PKC activators, while bilayer stabilizers are inhibi-
tors of the enzyme. In the present study we have also shown
a similar relationship between the synergistic effect of DO
and C6-ceramide on PKC activity and the increased ten-
dency of forming nonbilayer phases induced by DO and
C6-ceramide (Figs. 3 and 4). The synergistic effect of DO
and C6-ceramide on PKC is dependent on the concentration
of both lipid molecules before reaching the maximum PKC
activity that occurred at the combination of 15 mol % DO
FIGURE 3 Dependence of PKC activity on the concentrations of DO
and/or C6-ceramide.
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and 20 mol % C6-ceramide. Based on our NMR results, in
the presence of 20 mol % C6-ceramide and 15 mol % DO,
no nonbilayer phases were present at the temperature of
PKC activity assays (30°C). However, increasing the tem-
perature to 60°C resulted in the presence of nonbilayer lipid
phases, demonstrating the increased tendency of the bilay-
ers with this composition to form such phases. A further
increase in DO and/or C6-ceramide concentration(s) re-
sulted in the presence of nonbilayer lipid phases at the
temperature of PKC assays and a decrease of the PKC
activity, consistent with the notion that the actual presence
of such phases is detrimental for PKC activity. Lee et al.
(1996) have reported that C6-ceramide at concentrations of
up to 200 mol % to PS, and in the presence of 6.5 mol %
DO, has no effect on PKC activity. Lee et al. (1996),
however, used a mixed micelle assay for measuring PKC
activity, thereby eliminating the effects of C6-ceramide on
lipid bilayer structure.
Both natural ceramide and C16-ceramide analog induced
lateral phase separation of gel-like and liquid crystalline
phases into the PC/PS bilayers without a significant effect
on the activity of PKC, confirming that this type of mem-
brane perturbation is not relevant for PKC activity (Snoek et
al., 1988; Zidovetzki and Lester, 1992; Senisterra and
Epand, 1993; Goldberg et al., 1994). We have previously
shown that such ceramide-induced lateral phase separation
plays an important role in activating another membrane-
associated enzyme, extracellular phospholipase A2 (Huang
et al., 1998). PKC activity can also be modulated by the
coexistence of the domains with different lipid composi-
tions, such as DO-rich and DO-poor domains (Dibble et al.,
1996).
FIGURE 4 2H-NMR spectra of
DPPC-d62 in BLPC/DPPC-d62/DPPS
mixtures at 30°C (left) or 60°C
(right). (A, B) control; (C, D) with 15
mol % DO; (E, F) with 20 mol %
C6-ceramide; (G, H) with 15 mol %
DO and 20 mol % C6-ceramide.
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Holopainen et al., (1997) have recently reported forma-
tion of microdomains in dimyristoylPC/natural ceramide
mixtures. Addition of ceramide to dimyristoylPC resulted in
increased temperature of gel-to-liquid crystalline phase
transition, as followed by differential scanning calorimetry,
and increased polarization of a fluorescent probe in the
membranes. Poor mixing of natural ceramide with DPPC
was also recently reported by Veiga et al. (1999). These
results are consistent with those obtained by us in the
present study with PC/PS, and in the previous publications
with PC/ceramide (Huang et al., 1996, 1998) systems.
Moreover, the use of 2H-NMR allowed us to obtain the
superposition of spectra corresponding to the lipids in gel-
like and fluid liquid crystalline domains, directly demon-
strating the coexistence of the corresponding laterally sep-
arated phases. Noting that the average chain length of the
natural ceramide greatly exceeds that of dimyristoylPC,
Holopainen et al. (1997) suggested that the hydrophobic
mismatch is the main driving force of the ceramide-enriched
domain formation. We, however, obtained similar results
with natural ceramide or much shorter C16-ceramide using
either PC/PS system or DPPC system. We therefore con-
clude that the main contribution to the observed lateral
phase separation is, similarly to the effects of DAGs, the
lack of a bulky headgroup in the ceramide molecule, which
allows for closer chain interactions and complex-like for-
mation between ceramide and PC or PS molecules. These
phospholipid-ceramide complexes then laterally phase-sep-
arate from the bulk lipids. Such a process was described in
detail for DAGs (De Boeck and Zidovetzki, 1989, 1992;
Heimburg et al., 1992; Goldberg et al., 1994; Lo´pez-Garcı´a
et al., 1994; Quinn et al., 1995; Schorn and Marsh, 1996).
Ruiz-Argu¨ello et al. (1996), using a different lipid sys-
tem, have reported that, although both natural DAG and
ceramide induce fusion of sphingomyelin/PE/cholesterol or
PC/PE/cholesterol vesicles, the mechanisms and efficiency
of this process are not the same for the two molecules; it
was suggested that the difference may be due to the differ-
ent effects of DAG and ceramide in inducing nonbilayer
lipid structures. Indeed, our current and previous results are
consistent with this interpretation and suggest that the dif-
ferent effects observed by Ruiz-Argu¨ello et al. (1996) are
due to the difference in the acyl chain compositions of
natural ceramide and DAG. As described above, we have
found that the membrane effect of C16-ceramide is similar to
that of dipalmitin. However, the fatty acid compositions of
the natural ceramides and DAGs are different: 85% of
natural ceramide have long saturated acyl chains at the
second position (manufacturer information), whereas the
predominant acyl chain at the second position of natural
DAG is polyunsaturated, commonly arachidonic. Our pre-
vious studies showed that 25 mol % 1-stearoyl, 2-arachido-
noyl-sn-glycerol efficiently induces nonbilayer lipid phases
in PC/PS (Goldberg et al., 1995) and erythrocyte lipid
(Zidovetzki et al., 1993) systems, whereas natural ceramide
at 25 mol % induces only lateral phase separation in DPPC
(Huang et al., 1996) or PC/PS (this study). Natural cer-
amide, however, can induce nonbilayer lipid phases in pure
PE bilayers (Veiga et al., 1999).
FIGURE 5 2H-NMR spectra of DPPC-d62 in BLPC/DPPC-d62/DPPS
mixtures at 30°C. (A) with 25 mol % DO; (B) with 25 mol % C6-ceramide;
(C) with 25 mol % DO and 25 mol % C6-ceramide.
FIGURE 6 2H-NMR spectra of DPPC-d62 in BLPC/DPPC-d62/DPPS
mixtures with 15 mol % DO and 20 mol % natural ceramide. (A) 30°C; (B)
60°C.
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CONCLUSIONS
The present work demonstrated that synthetic short-chain
ceramides, widely used in research to investigate sphingo-
myelin-dependent signal transduction pathway, also acti-
vate PKC, the effect not exhibited by natural ceramide.
Caution, therefore, should be exercised when interpreting
the results of the effects of the short-chain ceramides on
cells. It has been pointed out that in the cells exposed to
1–10 M C2- or C6-cer the membrane concentration of
these ceramides reaches 1–10 mol % to the phospholipids
(Hannun, 1996), which is within the range of ceramide
concentrations where both membrane perturbation and PKC
activation were observed in this study. Moreover, compa-
rable concentration of natural ceramide is achieved after
prolonged response to tumor necrosis factor- or serum
deprivation (Hannun, 1996). Similar levels of DAGs were
observed in some cellular systems, exceeding 5 mol % in
PC12 cells (Altin and Bradshaw, 1990), human epidermal
A431 cells (van Veldhoven and Bell, 1988), human endo-
thelial cells (Whatley et al., 1993), and transformed 3T3
cells (Wolfman and Macara, 1987). We have found that the
distinct effects of natural ceramide and short-chain cer-
amides are even more pronounced in the presence of DAG.
Natural ceramide has little effect on the enzyme activity,
whereas C2-, C6-, and C8-ceramides strongly activate PKC
synergistically with DO.
The present results, combined with our previous studies
with various DAGs and unesterified fatty acids, provide
strong support to the hypothesis that the physicochemical
parameters of the lipid membranes play an important role in
the mechanism of PKC activation. The specific membrane
parameter associated with PKC activation is the increased
tendency to form nonbilayer lipid structures, promoted by
the addition of the lipids with high intrinsic curvature
(Gruner, 1989). Many cellular membranes exist under con-
ditions of high curvature stress, being close to the bilayer-
to-hexagonal phase transition (Rilfors et al., 1994; Rietveld
et al., 1994), and the physicochemical properties of these
membranes are expected to be quite sensitive to changes in
DAG and ceramide concentration, resulting in modulation
of the activity of PKC and other membrane-associated
enzymes.
The NMR work was performed with a GN500 spectrometer, funded by
National Science Foundation Grant DMB840491 and National Institutes of
Health Grant BRSG2507.
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